# Ozempic Cuts Depression Risk by 44% and Anxiety by 38%, Landmark 95,000-Patient Study Finds

*2026-03-22 22:03 UTC · Science · 1 min read*

> Landmark study of 95,000 patients finds Ozempic cuts depression risk by 44% and anxiety by 38%, with psychiatric care needs dropping 42%.

Semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety, and a 47% lower risk of worsening addiction, according to a major study published in The Lancet Psychiatry. The research tracked over 95,000 participants diagnosed with depression or anxiety across Swedish national registers between 2009 and 2022.

During periods when patients were taking semaglutide, the need for psychiatric care dropped by 42% compared to periods without GLP-1 use. Scientists from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia led the research. The related drug liraglutide showed an 18% lower risk of worsening mental illness.

Researchers suspect both lifestyle improvements and direct brain effects could be driving the results, though the study does not prove weight loss directly causes improved mental health. The findings add to growing evidence that GLP-1 drugs have benefits far beyond weight management.

## Sources

- [sciencedaily.com](https://www.sciencedaily.com/releases/2026/03/260322020250.htm)
- [news.ki.se](https://news.ki.se/diabetes-drug-ozempic-linked-to-better-mental-health)
- [euronews.com](https://www.euronews.com/health/2026/03/19/weight-loss-drugs-may-lower-the-risk-of-depression-anxiety-and-self-harm-study-finds)

---
TechTools News · https://techtools.cz/tools/news/article/979-ozempic-cuts-depression-risk-by-44-and-anxiety-by-38-landmark-95-000-patient
Česká verze: https://techtools.cz/tools/news/clanek/1013-ozempic-snizuje-riziko-deprese-o-44-a-uzkosti-o-38-zjistila-prelomova-studie-95
